Global Irritable Bowel Syndrome (IBS) Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Upcoming Report
  • May 2021
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Irritable Bowel Syndrome (IBS) Market, By Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), Medical Condition (IBS-Constipation, IBS-diarrhea, Mixed), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users (Hospitals, Clinics, Homecare Settings), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Irritable Bowel Syndrome (IBS) Market Market Analysis and Insights : Global Irritable Bowel Syndrome (IBS) Market

The irritable bowel syndrome (IBS) market is expected to grow at a CAGR of 12.45% in the forecast period of 2020 to 2027. Increase in the commercialization of existing products in different regions is the vital factor escalating the irritable bowel syndrome (IBS) market growth.

Irritable bowel syndrome (IBS) is defined as a common gastrointestinal disorder which affects the large intestine. Signs & symptoms of irritable bowel syndrome (IBS) includes abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and Mixed IBS

Rise in geriatric population will uplift the market growth, also rise in the prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, increase in the level of stress, and unhealthy diet, rise in the awareness programs regarding the treatment and management of irritable bowel syndrome and increase in the inclination toward IBS products that enhance therapeutic outcome, are some of the crucial factors among others driving the irritable bowel syndrome (IBS) market growth. Moreover, rising research and development for the better treatment of the product and rising demand for the treatment in emerging economies will further create new opportunities for the irritable bowel syndrome (IBS) market in the forecast period of 2020-2027.

However, lack of straightforward treatment, poor demand in under developed countries, rise in the no. of generic competitors and less government initiatives taken in this direction are the major factors among others acting as restraints, and will further challenge the irritable bowel syndrome (IBS) market in the forecast period mentioned above.

This irritable bowel syndrome (IBS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the irritable bowel syndrome (IBS) market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Irritable Bowel Syndrome (IBS) Market Scope and Market Size

The irritable bowel syndrome (IBS) market is segmented on the basis of drug type, medical edition, distribution channel and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drug type, the irritable bowel syndrome (IBS) market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron and others.
  • Based on medical edition, the irritable bowel syndrome (IBS) market is segmented into IBS-constipation, IBS-diarrhea and mixed.
  • Based on distribution channel, the irritable bowel syndrome (IBS) market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
  • The irritable bowel syndrome (IBS) market is also segmented on the basis of end-users into hospitals, clinics and homecare settings.

Irritable Bowel Syndrome (IBS) Market Country Level Analysis

The irritable bowel syndrome (IBS) market is analysed and market size information is provided by country, drug type, medical edition, distribution channel and end-users as referenced above.

The countries covered in the irritable bowel syndrome (IBS) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the irritable bowel syndrome (IBS) market due to increasing presence of key market players, increase in the well-established healthcare infrastructure, greater patient awareness, and a strong presence of novel products in this region. Europe is the expected region in terms of growth in irritable bowel syndrome (IBS) market due to rising commercialization of IBS products and rise in the prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain in this region.

The country section of the irritable bowel syndrome (IBS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The irritable bowel syndrome (IBS) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Irritable Bowel Syndrome (IBS) Market Share Analysis

The irritable bowel syndrome (IBS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to irritable bowel syndrome (IBS) market.

The major players covered in the irritable bowel syndrome (IBS) market report are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals In., Bausch Health, Synthetic Biologics, Inc., Ardelyx., Salix Pharmaceuticals, Mallinckrodt., Abbott Laboratories, LEXICON PHARMACEUTICALS, INC, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Ono Pharmaceutical Co., Ltd., Pfizer Inc, Novartis and Sebela Pharmaceuticals Inc among other domestic and global players. Irritable bowel syndrome (IBS) market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available : Global Irritable Bowel Syndrome (IBS) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions